DEF: STERIS plc Announces 2025 Annual General Meeting Agenda, Highlights Strong Fiscal 2025 Performance and Strategic Progress

Sentiment:

Proxy Statement 12 June 2025 4:23 PM

STERIS plc details its agenda for the 2025 Annual General Meeting, including director elections, auditor appointments, and proposals for share issuance authority, alongside reporting robust fiscal 2025 revenue growth and increased net income.

Capital raiseThe Board is seeking renewal of its authority to issue authorized but unissued shares under Irish law, up to 20% of the existing issued ordinary share capital (approximately 19,674,195 shares), until the earlier of the next annual general meeting or 15 months from the Annual Meeting.This authority is fundamental to the business and enables the company to issue shares, including for funding acquisitions and raising capital.The Board is also seeking renewal of its authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, up to 20% of the existing issued ordinary share capital (approximately 19,674,195 shares).For amounts greater than 10% of issued ordinary share capital (approximately 9,837,098 shares), this authority is to be used only for purposes of an acquisition or a specified capital investment.

Better than expectedFiscal 2025 revenue increased 6% to $5,459.5 million, indicating strong top-line growth.Net income significantly increased to $614.6 million from $378.2 million in the prior year, demonstrating improved profitability.Adjusted net income increased 5.3% to $924.3 million, reflecting core business strength.Cash flows from operations increased 18.0% to $1,148.1 million, showing robust cash generation.Free cash flow increased 26.9% to $787.2 million, highlighting strong liquidity and capital efficiency.Executive incentive compensation payouts were at 90% of target, indicating strong achievement of financial objectives, despite not reaching the maximum.

Summary

The 2025 Annual General Meeting of Shareholders of STERIS plc will be held on Thursday, July 31, 2025, at 9:00 a.m. Irish Standard Time (4:00 a.m. Eastern Daylight Time) in Dublin, Ireland.
Shareholders will be asked to vote on the re-election of nine incumbent directors and the election of one new director, Louis A. Shapiro.
Proposals include the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026, and the appointment of Ernst & Young Chartered Accountants as the Irish statutory auditor.
An advisory vote on the compensation of the company's named executive officers for fiscal 2025 is included, with the Board recommending approval.
The Board is seeking renewal of its authority to issue authorized but unissued shares under Irish law, up to 20% of existing issued ordinary share capital, and to opt-out of statutory pre-emption rights under Irish law for cash issuances, also up to 20% of existing issued ordinary share capital.
For fiscal year 2025, revenues increased 6% to $5,459.5 million, up from $5,138.7 million in fiscal 2024.
Net income for fiscal 2025 significantly increased to $614.6 million, or $6.20 per diluted share, compared with $378.2 million, or $3.81 per diluted share, in the prior year.
Adjusted net income rose 5.3% to $924.3 million, or $9.33 per diluted share, in fiscal 2025, compared with $877.6 million, or $8.83 per diluted share, in fiscal 2024.
Cash flows provided by operations increased 18.0% to $1,148.1 million in fiscal 2025, from $973.3 million in fiscal 2024.
Free cash flow increased 26.9% to $787.2 million in fiscal 2025, from $620.3 million in fiscal 2024.
The company successfully completed the divestiture of its dental business, utilizing the proceeds to reduce outstanding debt and strengthen its balance sheet.
Restructuring initiatives were executed, positioning the company to realize further cost savings in fiscal 2026.

Sentiment

Score: 8

Explanation: The document highlights strong financial performance in fiscal 2025 with significant increases in revenue, net income, and cash flow. It also outlines robust corporate governance practices and a compensation philosophy aligned with shareholder interests. While there's mention of litigation settlement costs and prior year loss from divestiture, the overall tone and reported results are very positive, indicating a well-managed company with clear strategic direction and proactive capital management strategies.

Positives

Fiscal 2025 marked another year of solid performance and strategic progress for STERIS.
Full year revenues increased 6% to $5,459.5 million, driven by continued strength in Healthcare and Applied Sterilization Technologies (AST) segments.
Net income increased significantly to $614.6 million, or $6.20 per diluted share, reflecting higher income from operations and lower interest expense.
Adjusted net income increased 5.3% to $924.3 million, or $9.33 per diluted share.
Cash flows provided by operations increased 18.0% to $1,148.1 million, reflecting improved earnings and enhanced working capital performance.
Free cash flow increased 26.9% to $787.2 million.
Successful divestiture of the dental business, with proceeds used to reduce outstanding debt and strengthen the balance sheet.
Execution of restructuring initiatives is expected to realize further cost savings in fiscal 2026.
The company has paid quarterly dividends each year since 2005 and increased the dividend to $0.57 per share during fiscal 2025.
The Board demonstrates strong independence, with all but one director and all Audit, Compensation, and Nominating/Governance Committee members being independent.
Robust stock ownership guidelines are in place for non-employee directors and executives, aligning their interests with shareholders.
Clawback policies are applicable to incentive compensation and equity awards, enhancing accountability.
A blanket prohibition prevents directors, officers, and employees from hedging, pledging, or short selling company shares.
Incentive-based compensation programs are directly linked to company performance, with 89.9% of CEO total compensation being variable in fiscal 2025.
Stock option awards for executives have a premium exercise price of 110% of the grant date fair market value, ensuring value is solely dependent on stock price appreciation.

Negatives

Fiscal 2025 net income was partially offset by a settlement associated with ethylene oxide litigation and higher restructuring expenses.
Fiscal 2024 net income was negatively impacted by a $206.4 million pre-tax loss recognized upon reclassification of the dental segment to assets held for sale and discontinued operations due to its divestiture.

Risks

Financial impact from ethylene oxide (EO) litigation, including settlement costs and associated legal expenses.
General legal, regulatory, quality, and health, safety, and environmental compliance risks.
Cybersecurity risks and the importance of safeguarding sensitive information and information systems integrity.
Risks related to the development, application, and protection of science, technology, and intellectual property.
Potential conflicts of interest, which are addressed by company policies and oversight.
Risks arising from compensation practices, though assessed as not reasonably likely to have a material adverse effect on the company.

Future Outlook

The company expects to realize further cost savings in fiscal 2026 from executed restructuring initiatives. It also anticipates additional peer group changes for future fiscal years due to further increases in company size resulting from acquisitions and other factors.

Management Comments

"Fiscal 2025 marked another year of solid performance and strategic progress for STERIS. We delivered 6% revenue growth, driven primarily by continued strength in our Healthcare and Applied Sterilization Technologies (AST) segments."
"These actions underscore our commitment to driving long-term value for shareholders through focused execution, financial discipline, and strategic capital allocation."
"Our 2025 compensation programs were intended to reward our CEO for generating value for our shareholders, as demonstrated by the following: 89.9% of total compensation delivered to our CEO was variable; 100% of annual incentive compensation delivered to our CEO was tied to annual financial performance measures based on Adjusted EBIT and Adjusted FCF, paying out an aggregate amount of $1,204,866 at 90% of target for fiscal 2025 with no adjustments based upon personal achievement."
"The Committee also believes that it must maintain flexibility in establishing compensation practices to allow it to address compensation trends, competitive issues, business needs, industry and the broader economic environment, and special situations that will be encountered in the recruitment, retention, and promotion of employees."

Industry Context

STERIS plc operates within the healthcare and life sciences industries, with a strong focus on healthcare and applied sterilization technologies. The company's strategic divestiture of its dental business indicates a move towards portfolio optimization and concentration on core, higher-growth segments. Its compensation peer group selection, comprising companies in healthcare equipment, supplies, and life sciences tools, further emphasizes its positioning within these specialized and growing sectors.

Comparison to Industry Standards

The company's executive compensation program targets base salaries, cash bonuses, and equity compensation within a general range of 15% above or below the market median of its peer group, aiming for competitive but not excessive pay.
As of September 30, 2023, the company's overhang from outstanding equity grants was between the median and the 75th percentile of its peer group, while total overhang (including shares available for future grant) was below the 25th percentile.
The company's three-year average share usage (2021-2023) was at the median of its peer group, indicating efficient management of equity dilution.
The company's three-year average fair value transfer (2021-2023) was below the 25th percentile of peers in absolute dollars, as a percentage of market capitalization, and as a percentage of revenue, suggesting a cost-effective equity program.
STERIS's financial and operational metrics at August 31, 2023, including annual revenue ($5.1 billion, 68th percentile), market capitalization ($22.7 billion, 55th percentile), and employee numbers (17,000, 67th percentile), generally fell within a reasonable range around the medians of its peer group.
The company's corporate governance practices, such as the requirement for shareholder approval for share issuance authority and opting out of pre-emption rights, are consistent with customary practices for public companies incorporated in Ireland and listed on U.S. markets, placing them on 'equal footing' with other NYSE-listed companies.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	N/A	Louis A. Shapiro	Following the Annual Meeting (if elected)	Identified as a director candidate by a third-party search firm and unanimously recommended by the Nominating and Governance Committee for election.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition/Independence	The Board maintains strong independence, with all but one director and all Audit, Compensation and Organization Development, and Nominating and Governance Committee members determined to be independent.	Ongoing (as of March 31, 2025)	Enhances oversight, reduces potential conflicts of interest, and aligns with best corporate governance practices.
Board Leadership Structure	The company maintains an independent, non-executive Chairman of the Board and a separate President and Chief Executive Officer, providing an effective balance between management and director participation.	Ongoing	Promotes effective governance and independent oversight of management.
Director Stock Ownership Guidelines	Non-employee directors are required to own company Ordinary Shares with a value of at least six times the cash portion of their annual fees, with new directors having a five-year period to satisfy the guidelines.	Ongoing	Further aligns the financial interests of directors with those of shareholders, encouraging long-term value creation.
Executive Stock Ownership Policy	The policy was expanded to include more key employees, requiring senior managers and other key personnel to maintain a significant equity interest in the company, expressed as a multiple of base salary (e.g., CEO: 6x, CFO: 4x).	Ongoing (most recently revised to formalize and expand coverage)	Reinforces the alignment of management's interests with shareholder value and promotes a long-term perspective.
Clawback Policies	Expanded clawback policies for annual incentive compensation and equity awards were adopted, compliant with new SEC/NYSE rules, allowing for forfeiture or return of awards if financial statements are restated due to intentional misconduct.	October 2, 2023	Strengthens accountability for executive performance and discourages misconduct related to financial reporting.
Restrictions on Securities Transactions	The company's Insider Trading Policy prohibits directors, executive officers, and employees from purchasing financial instruments that hedge or offset decreases in company share value, as well as short-term trading, short sales, option trading, and pledging.	Ongoing	Prevents conflicts of interest, discourages speculative trading, and promotes a long-term investment perspective among insiders.
Board and Committee Evaluations	The Board conducts annual self-evaluations and individual director evaluations to assess the effectiveness of the Board, its committees, and individual members.	Ongoing	Fosters continuous improvement in governance practices and board performance.
Majority Voting for Directors	In uncontested elections, if an incumbent director nominee does not receive a majority of votes cast, they must promptly offer their resignation to the Board, which will then consider and disclose its decision.	Ongoing	Enhances shareholder influence over director elections and promotes board accountability.

Legal Proceedings

Fiscal 2025 net income was partially offset by a settlement associated with ethylene oxide (EO) litigation.
Adjusted EBIT calculation for the Management Incentive Compensation Plan (MICP) excluded legal costs associated with Illinois EO litigation over $6 million.
Illinois EO litigation costs amounted to $16.0 million (for Adjusted EBIT calculation) and $12.2 million (for Adjusted FCF calculation) in fiscal 2025.
An Illinois EO litigation settlement of $48.2 million (for Adjusted EBIT calculation) and $5.0 million (for Adjusted FCF calculation) was recorded in fiscal 2025.

Stakeholder Impact

**Shareholders**: Expected positive impact due to strong financial performance, increased dividends, strategic portfolio optimization (dental business divestiture), and robust corporate governance practices aimed at aligning management and director interests with long-term shareholder value. The proposed share issuance authority provides flexibility for future growth and capital management.
**Employees**: Benefit from compensation programs designed to attract, retain, and motivate talent, including continued vesting after retirement for eligible equity awards. The company conducts biannual employee engagement surveys to focus on strengths and identify areas for improvement.
**Customers**: The company's mission to 'HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD' through innovative healthcare and life science products and services indicates a continued focus on customer value and safety.
**Creditors**: The use of proceeds from the dental business divestiture to reduce outstanding debt strengthens the company's balance sheet, potentially improving its creditworthiness and financial stability.

Next Steps

Hold the 2025 Annual General Meeting of Shareholders on July 31, 2025, where shareholders will vote on various proposals.
Management will present the company's statutory financial statements under Irish law for the fiscal year ended March 31, 2025, and a review of the company's affairs at the Annual Meeting.
Results of the polls taken on the resolutions at the Annual Meeting will be made available on the company's website and filed with the SEC on a Form 8-K within four business days.
Realize further cost savings in fiscal 2026 from executed restructuring initiatives.
Expect additional peer group changes for future fiscal years due to further increases in company size.
Hold the next non-binding advisory Say on Pay vote at the 2026 annual general meeting of shareholders.
Propose renewals of the Board's authority to issue shares and opt-out of statutory pre-emption rights on a regular basis at annual general meetings in subsequent years.

Key Dates

Date	Description
2020-04-01	Start of various compensation data periods for named executive officers and non-PEO NEOs.
2021-03-31	End of various compensation data periods for named executive officers and non-PEO NEOs.
2021-04-01	Start of various compensation data periods for named executive officers and non-PEO NEOs.
2022-03-31	End of various compensation data periods for named executive officers and non-PEO NEOs.
2022-04-01	Start of various compensation data periods for named executive officers and non-PEO NEOs.
2023-03-31	End of various compensation data periods for named executive officers and non-PEO NEOs.
2023-05-30	Date after which continued vesting after retirement for equity awards applies to eligible US employees.
2023-10-02	Effective date of expanded clawback policy compliant with new SEC/NYSE rules.
2024-03-31	End of fiscal year 2024 for financial reporting.
2024-08-01	Date shareholders ratified the appointment of Ernst & Young LLP for fiscal year ending March 31, 2025.
2025-03-31	End of fiscal year 2025 for financial reporting; assumed termination and change in control date for potential payments; date for stock price used in calculations ($226.65 per share).
2025-05-02	Approval date for fiscal 2025 equity awards.
2025-05-15	Date as of which approximately 2,037,695 million Ordinary Shares remained available for grant under the 2006 Plan.
2025-06-02	Record Date for shareholders entitled to notice of, and to attend, speak, ask questions and vote at the Annual Meeting.
2025-06-04	Grant date for fiscal 2025 equity awards (restricted stock and stock options).
2025-06-12	Date Proxy Statement first furnished to shareholders.
2025-07-25	11:59 p.m. Eastern Daylight Time, deadline for 401(k) Plan voting instructions.
2025-07-26	4:59 a.m. Irish Standard Time, deadline for 401(k) Plan voting instructions.
2025-07-29	11:59 p.m. Eastern Daylight Time, deadline for proxy voting.
2025-07-30	4:59 a.m. Irish Standard Time, deadline for proxy voting.
2025-07-31	Date of the 2025 Annual General Meeting of Shareholders (9:00 a.m. Irish Standard Time / 4:00 a.m. Eastern Daylight Time).
2026-02-12	Expected deadline for shareholders to submit proposals for inclusion in the proxy materials for the 2026 annual general meeting (Rule 14a-8).
2026-04-02	Earliest date for shareholder notice to nominate directors or bring other business for the 2026 annual general meeting (under Articles).
2026-05-02	Latest date for shareholder notice to nominate directors or bring other business for the 2026 annual general meeting (under Articles).
2026-06-01	Latest date for universal proxy notice for the 2026 annual general meeting.

Recommendation

strong buy

Keywords

Healthcare, Medical Devices, Sterilization, Life Sciences, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Financial Performance, Dividends, Shareholder Meeting, Board of Directors, Audit, Cash Flow, Acquisitions, Divestitures, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.